total leukocytes ( I , 2). Human newborns, assuming an average oral intake of about 0.1 L/kg/d over this period, will consume more than 2 billion PMN and as many mononuclear cells. These cells may offer the newborn some benefit by augmenting its immature host defenses. However. leukocytes in colostrum and breast milk function poorly compared with circulating white blood cells (3) (4) (5) (6) (7) (8) (9) . making it difficult to understand how they could augment host defenses. However, if the primary role of these maternal cells were to protect a mother's breasts as this new secretory pathway was established, then these cells may offer little immunologic benefit to the infant directly. If the PMN in colostrum continued to function normally, they might pose a threat to the infant's gastrointestinal tract mucosa because they could mediate inflammation and local tissue injury (10-13).
We hypothesize that antileukocyte activity in colostrum is needed to protect the newborn in this unique physiologic setting of mucosal exposure to exogenous PMN and that this antileukocyte activity results in a biologically significant anti-inflammatory effect. In vitro data directly demonstrate that human colostrum and milk have antileukocyte activity. Human milk and colostrum inhibit many peripheral blood (3-5. 14-16) and milk-derived leukocyte (3-9) functions in vitro. Human colostrum can protect cell monolayers from injury by activated PMN. and this protection is probably mediated by several antioxidant components ( 17. 18).
Inhibition of PMN activity by colostrum might be expected to result in suppression of acute inflammatory responses. Acute inflammation is a dynamic process involving tissue and circulating leukocytes, and the best evidence of a biologically significant anti-inflammatory effect is based on data from epidemiologic or in vivo experimental data. An anti-inflammatory effect of human C O~O S~N~ or breast milk in vivo has not been described; however, in humans, several epidemiologic phenomena suggest such an effect. Common respiratory and gastrointestinal infections are less frequent and severe in infants who are breast-fed (19. 20) . This protection may be mediated by specific anti-infective factors in milk, such as secretory immunoglobulin. lysozyme, lactoferrin. and oligosaccharides (2 1, 22). However. these infections represent the most common stimulus for inflammation in this population, and an anti-inflammatory effect of breast-feeding might be indistinguishable from an anti-infective effect. Enteric infection with pathogens that typically produce intestinal inflammation, such as Shigella, are commonly noninflammatory in breast-fed infants (23, 24) . Necrotizing enterocolitis also has been shown to be significantly less likely to occur in breast-fed infants (25). Although indirect, these associations suggest the possibility of anti-inflammatory activity in breast milk. Reviewing the available data, other investigators have found support for the hypothesis that breast milk is anti-inflammatory ( 19, 20) .
A well-described animal model of acute inflammation is used to examine whether human colostrum can alter the cascade of !08 events in acute inflammation leading to PMN accumulation locally and to compare the magnitude of this effect with those of known potent anti-inflammatory agents.
MATERIALS A N D METHODS
Coll~~c~tion c?/'colo.s~r~rm. Colostrum used for these studies was the lactational product obtained from inpatient mothers from 1 to 4 d postpartum after informed consent was obtained. No mothers had symptoms of mastitis. Mothers were not excluded because of premature delivery. The entire contents of one breast were obtained aseptically using an electric breast pump (Egnell, Cary, IL). Colostrum was immediately chilled and transported to the laboratory on ice. Specimens were then promptly separated by ultracentrifugation (LS-70, Beckman Instruments, Inc.. Palo Alto, CA) at 8 1 000 x g for 30 min at 4°C. The aqueous fraction was collected by puncturing the centrifuge tube with an 18-gauge needle and draining this fraction dropwise into a sterile plastic container. The cream layer and cell pellet were discarded. and the samples were frozen at -70'C until used. Samples of aqueous colostrum from at least six donors were thawed and pooled. Each pool of colostrum was filter-sterilized (0.45 pm) and stored at -70'C until used. Seven pools were used for these experiments. Individual donor colostrum was prepared similarly but not pooled. were housed six to a cage in a temperature-and ventilationcontrolled environment and given standard rat food and water ad libiliim. On d 0 after inducing COz necrosis, a 20-mL subcutaneous air pouch was formed in the midline of the back of each rat by injection of air, and pouches were refilled with 10 mL of air in a similar manner. Tails were marked for identification on d 3. On d 6. 5 mL of a challenge material, carrageenan, normal saline. or colostrum, were injected into the pouch. The effect of colostrum on inflammation was tested by injecting 5 mL of colostrum into the pouch immediately after carrageenan injection (Carr + Col). Animals were observed periodically for signs of local or systemic distress. Six h later. rats were killed using C 0 2 overdose and pouch fluid was promptly collected. Pouches were injected with 3 mL of heparinized PBS (loh U/L) and vigorously kneaded for 15 s. Skin overlying the pouch was shaved with electric clippers (Oster, no. 40 blade. Milwaukee. WI). and the pouch was opened with sharp dissection. Pouch fluid was drained and expressed into a plastic cup. The volume of fluid obtained was measured. and samples of pouch fluid were aliquoted. One aliquot of pouch fluid was diluted 1:10 with 10% formalin in PBS. and cell number determined using a hemocytometer. Differential cell counts were performed using cytocentrifuge-prepared slides (Shandon. Cheshire, England) of a fresh aliquot of pouch fluid, stained with a modified Wright's stain (Diff-Quik. Baxter. Miami. FL). In some cases, an aliquot of fluid was frozen at -70°C for assay of PMN granule contents at a later time. Scrapings and histologic examination of the pouch wall after pouch fluid collection showed no adherent white blood cells (wbc) on the pouch wall surface. The number of PMN per pouch was calculated as follows:
x cell number ( X IOh/mL) x wbc/cells X PMN/wbc ..ln~i-in/lutnma~or~~ ug~~nls. Dexamethasone (Decadron elixir) and indomethacin (Indocin oral suspension) were gifts of Merck Sharp & Dohme (West Point, PA). Either agent, dexamethasone (10 mg/L) or indomethacin (100 mg/L), was added to the animals' water supply for 3 d before and during challenge with carrageenan.
Cell .srahili~~~ in colo.s~riun. Human PMN were purified from heparinized whole blood of healthy adult volunteers by centrifugation over a Ficoll-Hypaque gradient, dextran sedimentation, and hypotonic lysis (26) and resuspended at 10" cells/L in HBSS. Autologous plasma diluted with one volume of HBSS was collected from the tops of the gradients after centrifugation and was filter-sterilized (0.45 pm). Thawed pooled aqueous C O~O S~N~ was similarly diluted and filtered. Triplicate samples prepared with 0.2 mL of PMN suspension and 3 mL of colostrum or autologous plasma were incubated in 5% moist COl at 37'C. Aliquots were taken at various time points. and absolute and differential cell counts were performed as for pouch fluid.
Leirkocj*lc~ granirlr tnarkcr u.s.sa~:s. Aliquots of frozen pouch fluid were thawed and sonicated (W185. Heat Systems-Ultrasonic. Plainview. NY) at 40 W for 30 s on ice after the addition of equal volumes HBSS-0. 1 % Triton X-100. Lysate supernatants were collected after centrifugation at 15 000 x g for 20 min at 4°C and stored at -70°C until used. ij-Glucuronidase activity was determined as previously described (27) by incubating 0.05 mL of lysate supernatant with 0.05 mL 2 mM 4-methylumbelliferyl-e-D-glucuronide (Sigma) in 100 mM acetate buffer (pH 3.5)-0.1% Triton X-100 at 37°C for 60 min. and then stopping the reaction with 2.4 mL of 50 mM glycine buffer (pH 10.4)-5 mM EDTA. Fluorescence of the samples was measured in a fluorescence spectrophotometer (650-10s. Perkin-Elmer, Oak Brook. IL). using 365-nm excitation and 450-nm emission wavelengths. The correlation between fluorescence and PMN number was excellent ( r = 0.997) over a range of 0. I to 35 x lo9 purified human PMN/L in HBSS.
Fruc~ionatiot~ c~/'c~olo.s~rirm. A pool of aqueous colostrum was thawed and diluted into two portions: one portion was fractionated whereas the other was not. The fractionated portion was separated by molecular size filtration into three fractions containing components with > 100 000-D. 100 000-to 10 000-D, and < I0 000-D molecular mass ranges. This portion was partially passed through a filter retaining molecules > I00 000 D (YM 100. Diaflow ultrafilters. Amicon. Beverly. MA) under nitrogen at 4°C with constant stirring. and the filtrate was collected. The retentate was washed once with one volume of normal saline when its volume reached 10% of original, and then this retentate was rediluted to the original starting volume with normal saline to produce the >100000-D fraction. The YMlOO filtrate was refiltered and washed using a 10 000-D cutoff filter (YM 10). and the filtrate collected. The 100 000-to 10 000-D fraction was prepared from the washed YMIO retentate in the manner described previously. The YM I0 filtrate was lyophilized (Cryolyzer. New Brunswick Scientific Co.. Inc., New Brunswick, NJ) and reconstituted with normal saline to the original sample volume to produce the <10 000-D fraction. The unfractionated portion of colostrum and the prepared fractions were stored together during this procedure and were frozen together at -70'C on completion. Table 1 . Animals .,liability in the inflammatory activity of these preparations was with pouches injected with normal saline had no visible change seen. Pouch fluid P~~ counts ranged from 82.7 + 9.7 10'
in behavior, no signs of local inflammation in the skin overlying P M N /~~~~~ ( n = 9) for the most active preparation to 13.2 the pouch, and little PMN influx into pouch fluid. Pouch fluid 8.2 106 p~~/~~~~h ( n = 4) for the least active preparation.
cell counts were 0.9 + 0.2 x lo6 PMN/po~ch for rmrmal saline This may be related to the poor-solubility of carra-(n = 31) over many experiments. Injection of colostrum resulted geenan in water. Precipitation was seen in the preparation with in no changes in rat behavior, no signs of local inflammation, the least activity, and this precipitate cleared and activity imand a modest PMN influx. Pouch fluid PMN counts were 4.3 f proved after reautoclaving the preparation. 0.8 lo6 PMN/pouch for colostrum ( n = 1 1) ( p < 0.001 for Variability r!fcolostral anti-inflammatory activitj'. A comparC0l versus C a n or normal saline). In a single pilot trial. the use ison of PMN responses in paired carrageenan and carrageenan of whole or acellular colostrum resulted in more PMN influx plus colostrum-treated animals was made for each carrageenan (10.1 or 9.8 x lo6 PMN/~ouch, respectively) than aqueous preparation used. Colostrum treatment resulted in mean decolostrum (4.5 X 10' PMN/pou~h). Injection of either of these crease~ in pouch fluid pMN counts of 22 to 85% in each cream-containing materials into the pouch resulted in the aCCu-carrageenan preparation examined, and these differences were mulation of many lipid-laden white blood cells, which made significant for three of the six preparations. Three of four prepaccurate cell counting difticult. Additional experiments were arations with seven or more animals in each carrageenan and performed only with Col.
colostrum plus carrageenan group produced significant differApproximately half the animals challenged with carrageenan ences, demonstrating that larger groups tended to show signifishowed decreased activity or ruffled fur but very few showed cant differences, as expected. Three of four carrageenan prepawarmth or tenderness over the pouch. These animals consistently rations with PMN responses of less than 50 x 106 PMN/pouch demonstrated the acc~mulation of large numbers of PMN in failed to show significant differences between carrageenan and pouch fluid. Pouch fluid PMN counts 6 h after carrageenan carrageenan plus colostrum-treated animals, demonstrating that challenge were 48.4 + 4.9 x 10' PMN/pouch ( n = 46, P < 0.001 a less inflammatory carrageenan preparation more often failed versus normal saline or Col). This significant cellular influx to demonstrate significant suppression. consisted almost exclusively of PMN (8 1 k 2%). No significant Seven pools of aqueous colostrum were used during the course differences in PMN responses were seen when comparing carra-of these experiments. PMN responses among paired carrageenan geenan prepared in PBS or normal saline (data not shown).
and carrageenan plus colostrum-treated animals were compared Effects of aqueous colostrum on acute inflammation. Injection for each colostrum pool used. Six of seven colostrum pools of colostrum immediately after carrageenan did not perceptibly produced mean decreases in pouch fluid PMN counts of 50 to alter the occurrence of behavioral changes compared with car-84%, whereas one pool showed a 10% decrease. Significant rageenan-challenged animals. The addition of colostrum to the suppression of PMN influx was present in four of seven pools. pouch consistently and significantly suppressed the influx of In a single experiment, aqueous colostrum samples from four PMN into pouch fluid in response to carrageenan. Pouch fluid individual donors were compared with a colostrum pool prepared PMN counts were reduced by an average of 6 1 % over the course from other donors. The pooled colostrum reduced the PMN of many experiments [18.8 + 2.9 verstds 48.8 f 4.9 x 10"MN/ influx in response to carrageenan by 52%. whereas the individual pouch (Carr + Col, n = 41, versus Carr, n = 46: p < 0.001)l. donor samples reduced the influx by 26, 27, 33, and 74%. These Relative activities of colostrum and anti-inflammatory agents. data indicate that anti-inflammatory activity in colostrum may Treatment with an anti-inflammatory agent before and during vary considerably among single samples from single donors. The challenge with carrageenan significantly suppressed PMN influx consistent anti-inflammatory activity in several pools of colosinto the pouch. Pouch fluid characteristics for animals concur-trum suggests that pooling six or more individual donor's colosrently challenged with carrageenan with or without anti-inflam-trum samples minimizes the variability among single donor matory agents or colostrum are shown in Carr). Pouch fluid PMN counts for colostrum-treated animals to 6.90 x lo9 PMN/L in colostrum over 6 h of incubation. Cell were reduced by an average of 85%, 8.0 k 2.9 X lo6 PMN/ counts at 24 h of incubation were 3.18 x lo9 PMN/L in plasma 
Volume ( fluid. An initial experiment using lysozyme as a PMN granule content marker revealed high levels of lysozyme activity in aqueous colostrum and in colostrum-treated pouch fluid and poor correlation with PMN counts in pouch fluid. Aqueous colostrum contained modest @-glucuronidase activity, and this PMN granule marker correlated well with PMN count in carrageenan and carrageenan plus colostrum-treated pouch fluid. In a single experiment, mean Pglucuronidase activity was 7.6 f 2.8 fluorescence units per 25 p L (units) (n = 2) in normal saline-treated pouch fluid samples, 34.2 + 1.7 units (n =2, p = 0.02 verslts normal saline) in colostrum-treated pouch fluid samples. 95.1 + 14.1 units (n = 7) in carrageenan-treated pouch fluid samples. and 54.9 + 5.4 units (n = 5, p = 0.04 versus Carr) in carrageenan plus colostrumtreated pouch fluid samples. If lysis of PMN was occumng in colostrum-treated pouches, increasing amounts of PMN granule contents would be seen as cells arrived and were lysed. This action would result in increased P-glucuronidase activity per observed leukocyte in colostrum-treated pouch fluids, independent of any added P-glucuronidase activity due to the colostrum itself. In pouch fluid from carrageenan-challenged animals, the relationship between (3-glucuronidase activity and the observed PMN count was 2.28 f 0.56 units per lo6 PMNImL ( r = 0.875, n = 7, p = 0.01) using linear regression analysis. In samples from animals challenged with carrageenan plus colostrum, the same relationship was 2.84 + 0.50 units per 10' PMN/L ( r = 0.956. n = 5, p = 0.01). The difference between these two slopes was not significant ( p = 0.49). suggesting that PMN granule contents were not accumulating in carrageenan plus colostrum-treated pouches as more PMN amved.
Anti-inflammatorj~ activitj, of tnolec~rlar sizing jractions (!/' aqueous colostr~tm. Separation of a pool of aqueous colostrum by molecular sizing filtration yielded three fractions. Treatment with unfractionated colostrum from the same pool decreased PMN influx after carrageenan challenge from 25.7 f 6.6 x IOh PMN/pouch to 2.4 + 0.3 x loh (Carr + Col. n = 3. vc.r.str.s Carr, n = 4, p = 0.03). Treatment with the colostrum fraction with components > I00 000 D produced a PMN influx of 30.6 f 3.8
x lo6 PMN/pouch (n = 3, p = 0.6 versus Carr). Treatment with the fraction with components from 100 000 to 10 000 D produced a PMN influx of 20.2 + 0.8 x lo6 PMN/pouch (n = 3, p = 0.5 vers1t.s Carr). Treatment with the fraction with components < 10 000 D produced a PMN influx of 6.9 + 4.0 x IOh PMN/pouch (n = 3, p = 0.08 versus Carr). Although the number of animals is small and significant suppressive activity of any fraction cannot be shown, these data suggest that anti-inflammatory activity in colostrum may be segregated to the low molecular weight fraction and that proinflammatory activity may be segregated to the high molecular weight fraction.
The rat air pouch model used in these studies is able to contain colostrum, challenge materials, and products of the inflammatory process for prolonged periods in contact with an organized tissue surface in vivo. Compared with other rodent models. this model can demonstrate inflammatory responses with good sensitivity (28-30). The model has been used previously to demonstrate the effects of known anti-inflammatory agents (31). Our experiments used observations of PMN numbers in pouch fluid as an end point because this parameter is closely associated with acute inflammation in vivo and can be estimated accurately and reproducibly in the laboratory. Our conclusions would not be altered if leukocyte influx instead of PMN influx into pouch fluid was used as the primary end point.
Carrageenan was used as the inflammatory challenge in these experiments because it is well studied and predictable in animal models of inflammation, and in preliminary trials it produced an impressive PMN response at an early point in acute inflammation. The diverse properties of carrageenan have been previously reviewed (32). Although gross signs of inflammation were infrequent, carrageenan challenge produced a significant cellular influx at 6 h postchallenge that was consistent with an acute inflammatory response. We conclude that carrageenan injection induces a prompt local acute inflammatory response in the rat air pouch.
For colostrum to protect newborns from inflammation, others have suggested that it first must be a poor inducer of inflammation (25). In these experiments, the inflammatory activity of colostrum was intermediate compared with the activity of normal saline or of carrageenan. Colostrum was less inflammatory than laboratory-prepared PBS that was used as a negative control in a single preliminary trial (data not shown) and that probably contained small amounts of endotoxin. We conclude that the aqueous phase of human colostrum is a poor inducer of acute inflammation in this model. The modest cellular response to aqueous colostrum injection might be related to the known chemoattractant activity of the major milk protein casein. The persistence of fluid in colostrum-injected pouches may reflect the higher osmotic activity of colostrum compared with the other challenge materials.
Pooled aqueous human colostrum significantly suppressed PMN influx after carrageenan challenge in these experiments. The degree of suppression was equivalent to those of potent antiinflammatory agents given systemically. The decreases seen in the presence of colostrum are most likely due to suppression of a component of the inflammatory cascade leading to PMN accumulation, because incubation of PMN in colostrum in vitro and correlation of leukocyte granule contents and cell counts in pouch fluid samples revealed no signs of significant PMN lysis. We conclude that colostrum can significantly alter acute inflammation in response to carrageenan challenge in the rat air pouch.
Whether decreases in the inflammatory response seen with colostrum treatment are the result of a specific anti-inflammatory activity was not examined. If colostrum possessed a specific
